APOA1 and metabolic dysfunction-associated steatotic liver disease: These results identify PPA as a critical microbe-derived mediator of the benefits apoA-I and suggest that the apoA-I–gut microbiota–PPA axis is a novel therapeutic target for MASLD (Figure 8).